Katsoula, AnastasiaTsapas, ApostolosLiakos, ArisSarigianni, MariaPaschos, PaschalisGiouleme, OlgaAthanasiadou, EleniBekiari, EleniBackground The aim of the study was to assess the efficacy and safety of tofacitinib and its impacton quality of life in patients with moderate-to-severe ulcerative colitis. Methods We conducted a systematic review and meta-analysis of randomized controlledtrials comparing tofacitinib with placebo or any active comparator. We searched Medline,Embase, the Cochrane Library and gray literature for articles published up to May 2017.We synthesized data using a fixed-effect model. We conducted subgroup analysis based onprior exposure to anti-tumor necrosis factor (TNF). We summarized the strength of evidenceusing the Grading of Recommendations Assessment, Development and Evaluation (GRADE)approach. Results We included three trials with 1220 participants. Compared with placebo, tofacitinib waseffective in inducing clinical remission (odds ratio [OR] 3.84, 95% confidence interval [CI] 2.29-6.44, I2: 41%, GRADE: moderate), clinical response (OR 2.95, 95%CI 2.21-3.95, I2: 0%, GRADE:high), mucosal healing (OR 2.70, 95%CI 1.81-4.03, I2: 0%, GRADE: high). Tofacitinib was effectivein both anti-TNF-naïve and -experienced patients. Tofacitinib had a favorable effect on qualityof life. There were no significant differences in the safety profile in terms of the incidence of anyor serious adverse events compared to placebo. The risk for infections was increased (OR 1.51,95%CI 1.05-2.19, I2: 0%, GRADE: moderate), but the incidence of serious infections did not differbetween tofacitinib and placebo. Conclusion In patients with moderate-to-severe ulcerative colitis, short-term treatment withtofacitinib is effective for induction of remission and improvement of quality of life. Keywords Tofacitinib, ulcerative colitis, meta-analysis Ann Gastroenterol 2018; 31 (5): 572-582text/htmlapplication/pdfhttp://www.annalsgastro.gr/index.php/annalsgastro/article/view/3986engHellenic Society of GastroenterologyCopyright (c) 2018 Annals of Gastroenterology1792-74631108-7471Annals of Gastroenterology; Volume 31, No 5 (2018); 572Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysisinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion2018-08-23Δημοσίευση σε περιοδικόPublication in journalΓαστροεντερολογίαGastroenterologyisi -Gastroenterology & Hepatology covers resources on the anatomy, physiology, biochemistry, and pathology of the digestive system. This category includes specific resources on the prognosis and treatment of digestive diseases; stomach ulcers; metabolic, genetic, infectious and chemically induced diseases of the liver; colitis; diseases of the pancreas and diseases of the rectum.Επιστημονικό άρθροScientific articleΕλληνική Γαστροεντερολογική ΕταιρίαGreek Aggregator OpenArchives.gr | National Documentation Centre (EKT)other